Royalty Pharma has acquired the rights to royalties on sales of Lexiscan and Cubicin from an undisclosed seller for $487 million.
Lexiscan (regadenoson) is a pharmacologic stress agent for radionuclide myocardial perfusion imaging (MPI) to detect and characterize coronary artery disease in patients unable to undergo adequate exercise stress.
Codeveloped by CV Therapeutics (now Gilead) and Astellas, Lexiscan tallied sales of $438 million in the U.S. in 2010. Lexiscan is marketed by Astellas in the U.S.
Cubicin (daptomycin) is the first antibiotic in a class of anti-infectives called lipopeptides. The bacteriocidal, intravenous antibiotic is designed to combat methicillin-resistant Staphylococcus aureus (MRSA).
Cubicin is marketed by Cubist in the U.S. and Novartis in the European Union. The product achieved sales of $600 million in the U.S. in 2010.
